ArticleProceedings of the National Academy of Sciences of the United States of America2018
Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- The IL-33-ILC2 axis: a key regulator of type 2 immunity in respiratory disease.Frontiers in immunology · 2026Review
- Mast cells: key players in digestive system tumors and their interactions with immune cells.Cell death discovery · 2025Review
- IL-33 signaling is dispensable for the IL-10-induced enhancement of mast cell responses during food allergy.Frontiers in immunology · 2025Article
- Studies of Structure-Activity Relationship of 2-(Pyrrolidin-1ylmethyl)-1ACS medicinal chemistry letters · 2024Article
- IL-10 Neutralization Attenuates Mast Cell Responses in a Murine Model of Experimental Food Allergy.ImmunoHorizons · 2024Article
- IL-10 Differentially Promotes Mast Cell Responsiveness to IL-33, Resulting in Enhancement of Type 2 Inflammation and Suppression of Neutrophilia.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- SCF and IL-33 regulate mouse mast cell phenotypic and functional plasticity supporting a pro-inflammatory microenvironment.Cell death & disease · 2023Article
- A Deep View of the Biological Property of Interleukin-33 and Its Dysfunction in the Gut.International journal of molecular sciences · 2023Review
- Review
- TCF-1: a maverick in T cell development and function.Nature immunology · 2022Review
- Article
- ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses.Cancer immunology research · 2021Article
- Mechanisms of Immunosuppression in Colorectal Cancer.Cancers · 2020Review
- Review
- Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor.Oncology letters · 2020Review
- IL-9 and IL-9-producing cells in tumor immunity.Cell communication and signaling : CCS · 2020Review
- Mast cells-derived MiR-223 destroys intestinal barrier function by inhibition of CLDN8 expression in intestinal epithelial cells.Biological research · 2020Article
- Beyond IgE: Alternative Mast Cell Activation Across Different Disease States.International journal of molecular sciences · 2020Review
- Mast Cells: Fascinating but Still Elusive after 140 Years from Their Discovery.International journal of molecular sciences · 2020Article
- IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Mast cells (MCs) are tissue resident sentinels that mature and orchestrate inflammation in response to infection and allergy. While they are also frequently observed in tumors, the contribution of MCs to carcinogenesis remains unclear. Here, we show that sequential oncogenic events in gut epithelia expand different types of MCs in a temporal-, spatial-, and cytokine-dependent manner. The first wave of MCs expands focally in benign adenomatous polyps, which have elevated levels of IL-10, IL-13, and IL-33, and are rich in type-2 innate lymphoid cells (ILC2s). These vanguard MCs adhere to the transformed epithelial cells and express murine mast cell protease 2 (mMCP2; a typical mucosal MC protease) and, to a lesser extent, the connective tissue mast cell (CTMC) protease mMCP6. Persistence of MCs is strictly dependent on T cell-derived IL-10, and their loss in the absence of IL-10-expressing T cells markedly delays small bowel (SB) polyposis. MCs expand profusely in polyposis-prone mice when T cells overexpress IL-10. The frequency of polyp-associated MCs is unaltered in response to broad-spectrum antibiotics, arguing against a microbial component driving their recruitment. Intriguingly, when polyps become invasive, a second wave of mMCP5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.